Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective hard but unsuccessfully to create a single therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the treatment of multi-drug-resistant HIV are actually closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past few shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set out the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely promotional image in the Uptick Newswire interview which I came away with a poor impression of the company.

Irony of irony, the poor viewpoint of mine of the company has grown steadily, yet the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise and also associated intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 zillion) along with the very first new drug application endorsement ($5 million), as well as royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to get a market place cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and numerous indications, it’s this individual treatment and a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

Its opening banner on its website (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple presentations and multiple publications.

Could all this be smoke and mirrors? That is a question I’ve been asking myself from the really start of the interest of mine in this organization. Judging by way of the multiples of thousands of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am much from alone in this question.

CytoDyn is a traditional battleground, or possibly some might say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *